Summary
The most common forms of acquired epilepsies arise following acute brain insults such as traumatic brain injury, stroke, or central nervous system infections. Treatment is effective for only 60%-70% of patients and remains symptomatic despite decades of effort to develop epilepsy prevention therapies. Recent preclinical efforts are focused on likely primary drivers of epileptogenesis, namely inflammation, neuron loss, plasticity, and circuit reorganization. This review suggests a path to identify neuronal and molecular targets for clinical testing of specific hypotheses about epileptogenesis and its prevention or modification. Acquired human epilepsies with different etiologies share some features with animal models. We identify these commonalities and discuss their relevance to the development of successful epilepsy prevention or disease modification strategies. Risk factors for developing epilepsy that appear common to multiple acute injury etiologies include intracranial bleeding, disruption of the blood-brain barrier, more severe injury, and early seizures within 1 week of injury. In diverse human epilepsies and animal models, seizures appear to propagate within a limbic or thalamocortical/corticocortical network. Common histopathologic features of epilepsy of diverse and mostly focal origin are microglial activation and astrogliosis, heterotopic neurons in the white matter, loss of neurons, and the presence of inflammatory cellular infiltrates. Astrocytes exhibit smaller K + conductances and lose gap junction coupling in many animal models as well as in sclerotic hippocampi from temporal lobe epilepsy patients. There is increasing evidence that epilepsy can be prevented or aborted in preclinical animal models of acquired epilepsy by interfering with processes that appear common to multiple acute injury etiologies, for example, in post-status epilepticus models of focal epilepsy by transient treatment with a trkB/PLCc1 inhibitor, isoflurane, or HMGB1 antibodies and by topical administration of adenosine, in the cortical fluid percussion injury model by focal cooling, and in the albumin posttraumatic epilepsy between the acute insult and the onset of clinically obvious epilepsy ( Figure 1) . 4 This postinjury interval offers an opportunity to intervene with treatment to prevent or delay epilepsy. No preventive treatment exists, yet few preventive studies have been conducted during the past 25 years despite the availability of a variety of drugs marketed for nonepilepsy indications that may have antiepileptogenic or disease-modifying effects in animal models. 3, [5] [6] [7] One reason for this is that-in the absence of prospective invasive electroencephalographic (EEG) data-the incidence of epilepsy after acute epileptogenic insults appears to be relatively low (eg, 20%-50% after moderate to severe TBI), and the clinical diagnosis of spontaneous ("late") seizures can take years, making clinical trials logistically challenging. Furthermore, there is uncertainty about whether the results of animal studies can be extrapolated to humans. The most commonly used animal models of epileptogenesis are post-SE models of temporal lobe epilepsy (TLE) and kindling models. The validity of applying results from these models to human epilepsy developing after TBI, CVA, or infections has not been established. In some implementations of fluid percussion injury (FPI; a model of TBI) with invasive EEG monitoring, only 20%-50% of the animals appear to develop epilepsy and their epileptic seizures are infrequent. 8, 9 However, optimization of the FPI model to maximize incidence and speed of epileptogenesis, and EEG montage to detect focal perilesional neocortical seizures, has resulted in a posttraumatic epilepsy (PTE) model that produces rapid epileptogenesis (>90% incidence of spontaneous seizures within 1 month of brain injury) and frequent seizures, including focal neocortical seizures that do not spread to the hippocampus, and this model has been successfully deployed in antiepileptogenesis studies. 10, 11 Clinical evidence points to common elements among the acute brain injuries that lead to human epilepsy (Figure 1) , which may provide insights into common mechanisms of epileptogenesis (Box 1 and Data S1). Although only a small proportion of patients with TBI, CVA, and infections develop epilepsy, certain subgroups of patients have a higher risk. Risk factors (Table 1 ) may provide insights into common mechanisms of epileptogenesis. The highest risk factors for epilepsy after acute injury include extravasation of blood due to breach of blood vessels (TBI with intracranial hemorrhage, CVA due to cerebral hemorrhage, or ischemic CVA with hemorrhagic conversion), severe injury, disruption of blood-brain barrier (BBB) with cerebral edema (encephalitis, febrile SE), early seizures occurring within 1 week after injury, and involvement of frontal or temporal lobes (Table 1 ). All but locus of injury are associated with an inflammatory response; other converging mechanisms by which these risk factors may promote epilepsy are discussed in Data S1. The focal epilepsies resulting from such brain insults (eg, TLE with hippocampal alterations or neocortical epilepsy, which can also involve hippocampal abnormalities) are often similar and reinforce the notion of commonalities in epileptogenic processes.
The purpose of this review is to examine the evidence for possible commonalities in epileptogenic processes among different causes of acute injury in humans, and among different animal models of acquired epileptogenesis. We attempt to answer the question of whether evidence from diverse animal models can be applied across the different common causes of human epilepsy after acute injury, and be utilized in translational studies of epilepsy prevention.
Clinical evidence for commonalities in focal epilepsies resulting from different acute injuries in adults and children is described in more detail in Data S1.
| ACUTE BRAIN INJURY EEG FINDINGS AND HOW THEY RELATE TO LATER EPILEPSY
The similarities in acute EEG findings in a variety of acute brain injuries are much more striking than the differences. Nonconvulsive seizures are seen in 13%-25% overall, and are increasingly seen with more cortical involvement, more intraparenchymal blood, acute clinical seizures, and the presence of coma. 12, 13 Similarly, spreading depolarizations (a form of peri-injury spreading depression seen on intracranial EEG) are common in a variety of acute brain injuries, including subarachnoid hemorrhage, TBI, spontaneous intraparenchymal hemorrhage, and malignant ischemic stroke. 14 
Acute
Key Points
• Epileptogenesis after common acute brain insults shares enough features to consider it one broad category
• We identify clinical and preclinical commonalities in epileptogenic processes and their relevance to successful epilepsy prevention strategies
• SE model findings should be corroborated in trauma and stroke models to see whether in the future SE data can be used to support human studies
• Preclinical evidence for several recently identified preventive therapeutic strategies can be followed in human studies
nonconvulsive seizures, periodic discharges, and spreading depolarizations have been independently correlated with adverse physiological effects and worse neurological outcomes in numerous studies. 15 Only a few investigations have looked at the later development of epilepsy based on acute EEG findings, but they seem to have predictive value as well. For example, a study of children undergoing continuous EEG monitoring in the pediatric intensive care unit showed that 47% of those with acute symptomatic electrographic SE went on to develop epilepsy, versus 11% in those without this EEG finding. 16 Electrographic SE had an odds ratio of 13.3 for development of epilepsy; it was also associated with worse functional outcome and quality of life. In a study of >100 survivors who had lateralized periodic discharges (LPDs) or nonconvulsive seizures (NCSzs), new development of epilepsy was seen in 17% of those with LPDs only, 38% with NCSzs only, and 48% with both LPDs and NCSzs. 17 Thus, patients with these acute EEG findings may be an appropriate cohort for epilepsy-prevention trials.
In critically ill patients, invasive EEG reveals seizures and periodic discharges in a higher percentage of patients than can be seen on scalp EEG, some of which appear to be causing metabolic distress. 18, 19 Whether these findings will predict later epilepsy and whether detection of acute high-frequency oscillations (HFOs) with this type of F I G U R E 1 Epileptogenic processes and risk factors involved in development of epilepsy after acute brain insults: a conceptual view.
Possibly depending on crucial modifiers or risk factors, the same brain injury can be epileptogenic or not. In the majority of patients, brain insults do not cause epilepsy, as discussed in the text. Furthermore, as illustrated in the figure, not all epileptogenic processes, once initiated, result in epilepsy, that is, complete their course to clinically obvious disease. The term epileptogenesis includes processes that render the brain susceptible to spontaneous recurrent seizures and processes that intensify seizures and make them more refractory to therapy (progression). During epileptogenesis, multiple brain alterations occur, including altered excitability of neurons and/or neuronal circuits, activation of microglia, astrocyte dysfunction, alterations in expression and function of receptors and ion channels (in part recapitulating ontogenesis), loss of neurons, neurogenesis, axonal and dendritic sprouting, gliosis, inflammatory processes, and more. It is important to note that some of these alterations may be related to postinjury repair or recovery and not suited as targets to halt the epileptogenic process. The figure has been modified from previous versions 3, 15, 273 [Color figure can be viewed at wileyonlinelibrary.com]
recording will be as predictive as they are in animal models 20 remain to be determined.
Thus, there appear to be commonalities in the acute EEG findings and in their prognostic significance, regardless of the specific type of acute brain injury. However, there has been minimal work on whether serial scalp EEGs can detect those patients who are in the process of developing epilepsy, or whether the specific type of acute brain injury matters once a given pattern is seen.
| GENETIC ASPECTS IN PATIENTS
There is little doubt that genetic factors have a role in the likelihood of developing epilepsy after acquired acute brain insults. The study of the genetic basis of familial epilepsies with Mendelian inheritance and the epileptic encephalopathies has clearly established the role of genes expressing ion channels, components of synaptic machinery, and other cellular determinants of network excitability. 21, 22 Some of these same genetic variants (eg, DEPDC5, LGI1, PCDH19, SCN1A, GRIN2A, KCNQ2, GABRG2, and others) are weakly associated with common forms of nonacquired epilepsy where a genetic basis is suspected given there is no identifiable insult or lesion. 23 Thus, as suggested decades ago, 24 it is highly likely that variants in these and other genes in normal humans influence the likelihood of developing epilepsy after acute brain injury. This concept is supported by the observation that the genetic background of rodents can be a major determinant in the development of chronic, recurrent seizures following a variety of brain insults. 25 The observa- • Diffuse brain damage is more likely to result in pharmacoresistance than other substrates for focal epilepsy,
• Posttraumatic epilepsy and postinfectious epilepsy are commonly severe and refractory to treatment,
• Epilepsy develops sooner and with higher incidence in children following SE or with nonfebrile cause than for febrile SE, and
• Drug response is surprisingly similar for epilepsy after stroke, vascular malformation, and tumor.
For further details, see Table S5 and Data S1. SE, status epilepticus.
FINDINGS IN FOCAL HUMAN EPILEPSIES
The neuropathology in 9523 patients with focal epilepsy and epilepsy surgery in 36 European centers was recently reviewed (European Epilepsy Brain Bank; for details see Bl€ umcke et al. 42 ). Thirty-six histopathology diagnoses were described, classified into 7 categories. Hippocampal sclerosis, brain tumors, and malformations of cortical development (MCD) were most common, accounting for 78.8% of the series. Seventy-two percent of lesions were located in the temporal lobe, compared to 13% in frontal lobe and 9% in multiple lobes.
The following structural commonalities were identified:
1. Reactive astrogliosis is always visible in epilepsy surgery specimens. 43 In the neocortex of patients with epilepsy, astrocytes are typically activated at the BBB or blood-cerebrospinal fluid barrier ( Figure 2A ). In subcortical white matter, fibrillary (or spider) gliosis can be seen. It is difficult to microscopically identify single astrocytes in this condition, as they are covered and hidden by a dense meshwork of spider-like ramifying processes ( Figure 2B ). This pattern is the likely cause for neuroimaging changes in white matter of patients with TLE. 44 Astrocytes may play a significant role in epileptogenesis (see separate section below). 2. Excess of heterotopic neurons in white matter can be seen in many epilepsy surgery specimens, such as hippocampal sclerosis or MCD ( Figure 3 ). This is referred to as "mild malformation of cortical development" when detected only as microscopic abnormality. 45, 46 Heterotopic neurons are rare in other brain diseases, but are consistently reported in epilepsy. 45, 47, 48 No pathomechanistic hypotheses have been developed yet from this observation. 3. White matter angiopathy is also common, 49 seemingly unrelated to a specific disease category, but associated with early seizure onset and long seizure duration. 4. Inflammatory cellular infiltrates are frequently found.
Lymphocytic infiltration can be provoked during perisurgical manipulation of brain tissue. Intracranial neurophysiology techniques applied during presurgical evaluation can also induce a mixed lymphocytic-microglial signature.
A common feature of these histopathologic findings is anatomical localization in the white matter, which in epilepsy is an insufficiently studied anatomical compartment.
The epileptogenic lesion is connected via axonal projections to its target regions, together referred to as the seizure network. In focal epilepsy, synchronized activation within the seizure network produces the clinical semiology. As yet, we have neither basic nor clinical evidence for seizures arising directly from white matter.
In addition to these histopathologic findings, epigenetic alterations may be involved in epileptogenesis. 50 Electrical membrane activity transmits directly into the cell nucleus, thereby driving and adjusting a neuron's response, including molecular memories that underlie long-lasting response to the environment, that is, the molecular memory of a neuron. 51 Epigenetic histone code modification and longlasting DNA methylation are a hallmark of molecular memory. 52 Increased DNA methylation patterns occur in various animal models of epilepsy and in drug-resistant human epileptic brain tissue. 50, [53] [54] [55] [56] It can be hypothesized that sustained epileptic activity alters the molecular memory of a neuron, promoting the development of a chronic epileptic state, which can be termed "epileptogenic memory." 
| COMMONALITIES IN ROUTES OF SEIZURE PROPAGATION FROM DIFFERENT EPILEPTIC FOCI
Commonalities in the pathways of seizure propagation are likely a function of the underlying network architecture, with circuits permissive to reentrant activity being particularly vulnerable to ictogenesis. 57 In some models of epilepsy (eg, amygdala kindling, intrahippocampal kainate injection) primary injury is localized, whereas in others (eg, SE) injury is diffuse, yet generally the seizure phenotype is the same. 58 Injuries after TBI, hypoxia/ischemia, or infection may likewise be focal or diffuse, and similarly engage 2 primary networks when propagating beyond the initial focus: (1) the limbic seizure network seen in TLE; and (2) a thalamocortical network similar to that seen in absence epilepsies, characterized by bilateral spike-andwave discharges and behavioral arrest. Simply put, because the routes of seizure propagation are constrained by anatomy, 59 so are the electrographic and behavioral responses to epileptogenic insults ( Figure 4 ). In most SE models, subcortical and temporal cortical damage is thought to drive seizure generating network(s). 60 In many of the TBI-and stroke-induced epilepsy models, however, the seizure onset zone is likely located in the corticothalamocortical network, although comprehensive studies remain to be done. [61] [62] [63] [64] [65] The hippocampus, amygdala, and piriform and entorhinal cortices are low-threshold entry points into the limbic seizure circuit. 66, 67 Conceptually, nodes of this network can be thought of as drivers (eg, cortical regions, hippocampus, amygdala) and distributors (eg, midline thalamus) that relay ictal activity from the driver focus to a broader network ( Figure 4A ). The thalamocortical network has been best examined with absence seizures; corticothalamic drivers recruit intrathalamic distributors, which in turn recruit thalamocortical drivers ( Figure 4B ). Although the nonconvulsive focal seizures reported in acquired models typically have a higher frequency than that of genetic absence bilateral seizures, they might engage the same circuits. 63, 68, 69 In both of these circuits, primary components may be modulated by inputs that, although not central to ictogenesis, can influence patterns of excitation and/or gate seizure activity. Perilesional focal seizures or pathological HFOs at the site of injury often predominate in the early postinjury phase and precede the development of limbic or thalamocortical spreading seizures. 20, 70, 71 Although HFOs are behaviorally silent (ie, purely electrographic), nonspreading perilesional focal seizures induce behavioral arrest when occurring in the frontal neocortex, 62 but appear behaviorally silent when occurring in the parietal or occipital neocortex. 71, 72 The emergence of seizure activity beyond the injury site may be thought of as secondary epileptogenesis. Seizure activity evoked by direct activation of cortical drivers gains rapid access to the limbic seizure network by virtue of corticocortical projections, corticothalamic projections, and projections from cortex to subcortical drivers. [73] [74] [75] [76] Similarly, subcortical foci recruit cortical seizure involvement through direct projections and through distributors. 77, 78 Cortical foci may likewise recruit the thalamocortical circuit. 79 In many models, for example, focal suppression of activity in the thalamus is potently anticonvulsant, 63, 78, 80, 81 and the same is true in patients with drugresistant types of focal epilepsy. 82 Direct injury to cortical drivers after TBI-frontal, parietal, or occipital-directed FPI-all trigger pathology in hippocampus, and are associated with both limbic seizures and thalamocorticallike seizures that present-just as in humans -different clinical correlates depending on the ictal sites. 69, 70, 72 Suppression of ventrobasal neuron activity after cortical infarct inhibits seizures in both the cortex and thalamus, 63 suggesting that just as in some evoked models (eg, cortical penicillin), activity in the thalamus is necessary to maintain cortical seizures. 79 Direct injury to subcortical drivers (eg, hippocampus after TBI) is unsurprisingly associated with primary seizure onset zones in the hippocampus. However, seizure onset has also been reported in other nodes of the network, including cortical drivers such as piriform cortex. 83 This pattern is similar in rats and humans, where even within a single subject, seizures may initiate at different foci. [84] [85] [86] Direct injury to cortical drivers after TBI is particularly informative; frontal, parietal, and occipital-directed FPIs all trigger pathology in hippocampus, and are all associated with both limbic seizures and thalamocorticallike seizures. 70, 72 Primary injury to the hippocampus after focal herpes encephalitis [87] [88] [89] or Theiler's murine viral encephalitis [90] [91] [92] is likewise associated with hippocampal seizures. 93 Secondary injury to subcortical drivers is also seen after TBI, controlled cortical impact (CCI), and photothrombotic CVA lesions. These changes in hippocampus along with primary cortical injury may underlie the decreased resting state blood oxygenation level-dependent contrast 94 and the decreased cortical and hippocampal glucose utilization reported after FPI. 95 In addition to the temporal lobe seizure phenotype seen in some models, several models of acquired epilepsy display nonconvulsive focal seizures. Brief focal seizures with accompanying behavioral arrest have been reported after FPI, ballistic injury, and ischemic injury in rats. 63, 68, [96] [97] [98] These are associated with injury to cortical drivers 61, 62, 69 and alterations in gene expression and physiology in intrathalamic distributors and drivers. 99 The relevance of these discharges to acquired epilepsies in humans is debated. 71, 100, 101 Cases in which seizures originate from sites distal to the injury are perhaps the most interesting and suggest that insults can exert epileptogenic effects by engaging a constrained set of networks. Although a great deal is known regarding these networks in evoked seizures and classic models, little network mapping has been conducted following TBI, hypoxia/ischemia, or infection. Even fewer studies have directly manipulated the primary seizure circuitry in these models, 63 and no studies have manipulated modulators (eg, basal ganglia, cerebellum) after these insults, although they gate a wide variety of seizures in other models. [102] [103] [104] [105] These areas of future exploration may prove essential to determining the degree of network overlap among these models and other models of acute or acquired epilepsy, and may likewise guide network-level interventions for acquired epilepsies.
| COMMONALITIES IN CIRCUIT REORGANIZATION AFTER ACQUIRED BRAIN INJURIES
Acquired (but also inherited) brain injuries result in complex network reorganizations. To paraphrase Eccles, Ito, and Szent agothai's classic book, one can see "epilepsy as a neuronal plasticity machine." It is difficult to pinpoint a network parameter that is not changed in epilepsy. Moreover, other than those with epileptic encephalopathies, seizures are usually rare events even in people with severe epilepsy (a person with daily seizures will still spend 99.9% of the time not having clinical seizures), pointing to the existence of compensatory mechanisms, which most of the time prevent clinical seizures from occurring. Electrophysiological changes in epileptogenesis and ictogenesis are therefore difficult to interpret, as they could constitute compensatory mechanisms, reflecting a different organization of neuronal circuits to carry out the same tasks.
The most obvious reorganizations commonly found in patients and animal SE models of epilepsy are cell loss, particularly of c-aminobutyric acidergic (GABAergic) interneurons, [107] [108] [109] reactive synaptogenesis and axonal sprouting, in particular from glutamatergic neurons, [110] [111] [112] [113] and the molecular reorganization of glutamate and GABA receptor subunits. [114] [115] [116] Many of these features are also found in TBI models, such as the sprouting of excitatory axons, the increase in excitatory drive, and the decrease in inhibitory drive. 117, 118 However, some changes, for example, GABA subunit changes during epileptogenesis, may be insult-specific. 119 Whether these modifications are similar in animal models and patients is difficult to address. In humans, the lack of proper control tissue (peritumoral nonepileptogenic tissue is usually used as control) prevents an appropriate comparison. Despite this caveat, commonalities are clearly apparent. Do these changes cause similar network consequences?
In rodent models and humans, a loss of interneurons results in decreased GABAergic synaptic (phasic) inputs. 120, 121 However, phasic inhibition is decreased in the dendrites but increased in the soma in pyramidal cells, 121 despite a reduction in GABA quantal release. 122 GABA also exerts tonic inhibition of neurons via activation of extrasynaptic receptors. In animal post-SE epilepsy, TBI, and stroke models and in human epilepsy, there is a preservation (or an increase) in tonic inhibition, despite the decrease in phasic inhibition. [123] [124] [125] [126] The computational consequences of the shift of GABAergic inhibition from dendritic to somatic results in inhibitory drive being more capable of synchronizing principal cells, and the shift of inhibition from phasic to tonic results in an increase in the gain of neurons, while preserving their baseline excitability. 121, 127 The predicted net result is an increase in synchronization and excitability during periods of increased network activity. Large-scale realistic computer models now exist to test this prediction directly. 128 The inhibitory action of GABA depends upon the reversal potential of Cl -currents (E Cl ). A minority of neurons in human slices show altered E Cl making GABA depolarizing, 129 ,130 a result reproduced in rodent models but only before animals developed spontaneous seizures. 131 Interictal activity appears to depend upon depolarizing GABA in vitro. 129, 130 In experimental models in vivo, interictal activity originates from interneuron firing. 132 Interneurons may play opposing roles during the progression and spread of seizure activity, and these roles may be determined both by the synchronizing effects of somatic inhibition and the propensity for inhibition to become depolarizing during excessive activity. 133, 134 Glutamatergic drive is also increased in epileptogenic tissue from humans 135 and rodents, 113 with an increased contribution of N-methyl-Daspartate receptors, which contribute to the bursting response.
136-138
Finally, acquired channelopathies, which could change the excitability and integrative properties of cells, have been described in experimental models. 139, 140 Interestingly, genetic overexpression of Kv1.1 K + channels can be disease modifying in experimental models. 141 These issues remain to be investigated in human tissue. Commonalities in electrophysiological alterations extend to seizures themselves. Seizure dynamics appear to follow general rules across species (from flies to humans) and brain regions, 142 but whether electrophysiological commonalities can "explain" epilepsy is not known, as, for most, no causal link has been established. There are many different biophysical paths to seizures in any given neuronal circuit, 142 and it is likely that, in most cases, the electrophysiological changes that occur just reflect lowered threshold for seizure genesis and/or facilitated seizure propagation. 143 
| COMMON HIPPOCAMPAL AND PARAHIPPOCAMPAL CIRCUITS AND STRUCTURAL LESIONS
Many animal models of epileptogenesis involve structural etiologies, for example, TBI, stroke, and cortical dysplasia. 144 A variety of seemingly unrelated insults, including head trauma, prolonged febrile seizures, vascular abnormalities, and encephalitis, can cause similar hippocampal pathology 43, [145] [146] [147] and the same seizure disorder, that is, acquired mesial TLE with hippocampal sclerosis. 148, 149 The hippocampal and temporal cortical damage after experimental SE resembles that found in resected tissue of patients with refractory TLE of different etiologies, including loss of dentate hilar and hippocampal pyramidal cells, layer III damage in the entorhinal cortex, gliosis, and mossy fiber sprouting. [150] [151] [152] Notably, dentate hilar neuron loss (endfolium sclerosis) was reported to be the single common pathology in epilepsy patients with any detectable hippocampal pathology. 145 TBI models induced with CCI or lateral FPI result in loss of hilar cells, mossy fiber sprouting, gliosis, and neurogenesis, whereas granule and pyramidal cell damage is less severe than in SE models. 153 Hippocampal inhibitory neurons appear particularly vulnerable to lateral FPI. 154 In correspondence with animal models, a subpopulation of patients with TBI shows progressive hippocampal volume loss and white matter atrophy on magnetic resonance imaging (MRI). 155, 156 Taken together, hippocampal atrophy is often seen in acquired epilepsy patients and experimental models. However, no study has compared hippocampal pathology between experimental models or humans with or without post-SE, post-TBI, or poststroke epilepsy, which is critical to pinpoint epileptogenesis-specific pathologies. 8 In some rodent models, prolonged dentate granule cell discharge selectively destroys vulnerable hippocampal neurons that control granule cell inhibition, 107, 157 thus weakening the normal gating function of the dentate gyrus. [158] [159] [160] [161] [162] Mild to moderate fluid percussion injury can also cause selective hilar neuron loss and granule cell hyperexcitability. 163 Why do dissimilar insults sometimes produce similar pathology and the same neurological condition? A central role has been proposed for excitatory dentate hilar mossy cells in establishing granule cell inhibition via activation of inhibitory neurons, 157 refute or confirm the "dormant basket cell" hypothesis. 150, 165 Regardless of the network mechanism underlying injury-related granule cell hyperexcitability, the selective loss of entorhinal cortex layer III neurons 166 and dentate hilar neurons 157 may be a common pathology produced by different insults.
An alternate perspective holds that epileptogenesis requires prolonged molecular and/or structural changes triggered by acute brain injury, because epilepsy develops only after a seizure-free period that can last for decades. 167 In this scenario, during the period from insult to clinical epilepsy the epileptogenic mechanism gradually elaborates. 65, 168, 169 Hippocampal transcriptomics and miRNA changes in SE and TBI models and in human TLE have been studied in an effort to identify critical pathways (Figure 5 and Tables S1 and S2 ). Very few similarities have been identified in hippocampal transcriptomics and miRNA Tables S2 and S3 . Biological functions/processes were collected from the gene ontology (GO) or pathway analyses performed in each study. The data were organized to align with different phases of epileptogenic process (acute postinjury time point, latency phase, and epilepsy phase). Word clouds were generated using the Wordcloud for R Package. For the sake of clarity, the words: "regulation," "cell," "cells," "process," and stop words ("English") were removed from the figures. All other words presented in original articles were included (minimum frequency = 1). The larger the word font size in the cloud, the more often the word appeared (eg, in the DAVID or IPA analyses). Note that there were differences in the original analyses, for example, in the terminology used to name different classes of biological functions and use of cutoff probability values (eg, analyses performed by DAVID or IPA). Also, the word cloud generated from the human data in panel B is not unbiased (asterisk), as it was extracted from the text (no pathway or GO analysis was presented by authors). Major differences between models were observed, especially when predicted miRNA target-regulated processes were compared (B). Status epilepticus (SE) models appeared to be more similar to each other than with traumatic brain injury (TBI) [Color figure can be viewed at wileyonlinelibrary.com] networks among the various structural models, even when data from the same etiology (eg, SE models) are compared, or between the experimental data and the sparse data available from human epileptic hippocampus. However, comparison of these findings has been difficult because of variability in cell types, tissue sampling, timing of tissue sampling during the course of epileptogenic process, analysis platforms, brain regions, methods for inducing injury, age and species of animals, and unknown epilepsy phenotype of animals sampled at early time points. Dingledine et al. overcame some of the methodological difficulties. 169 They performed a well-powered transcriptomics analysis of laser-dissected dentate granule cells in 3 different SE models, each model generated in 2 laboratories, used the same analysis platform, and found only 4.5% concordance of differentially expressed genes among the models. The same hippocampal network that can serve as a primary seizure source when the hippocampal formation is injured may play a secondary role when seizure activity from extratemporal foci spreads to, and recruits, the hippocampal formation.
170 Several brain regions innervate and influence the hippocampal formation, including nontemporal neocortex, thalamus, amygdala, and septum, 171 and it is likely that both the damaged and undamaged hippocampus can generate the same clinical signs regardless of where seizures start. Seizures that originate from temporal neocortical and even extratemporal neocortical foci may propagate to the hippocampal formation in both humans 172, 173 and rodents. 70 In sum, qualitative similarities in hippocampal pathology are evident among the SE, TBI, and stroke models as well as between experimental and human TLE triggered by these etiologies. These deserve further analysis in the context of the search for biomarkers (Box 2, Table S3 , and Data S2) and treatment targets of epileptogenesis.
| DYSFUNCTIONAL ASTROCYTES AND MICROGLIA: COMMONALITIES IN EPILEPTOGENIC PROCESSES
A common pathological hallmark in the sequence of events converting a normal brain into an epileptic brain after an acquired insult is microglial activation and subsequent astrogliosis, which result from inflammatory processes. [174] [175] [176] [177] Astrocytes regulate and amplify immune-mediated mechanisms implicated in epileptogenesis. 174, [178] [179] [180] [181] [182] [183] Reduced astrocyte coupling was also reported after acute CVA in situ. 194 Whether glial coupling is affected after TBI is unknown. One study observed enhanced phosphorylation of Cx43 protein in astrocytes after experimental TBI, 195 but functional coupling was not assessed. Albumin extravasation into the brain following focal injury causes inflammation and activation of a TGF-b pathway in astrocytes, which impairs K + homeostasis and leads to epilepsy. Importantly, treatment with losartan, a clinically used angiotensin II type I receptor inhibitor, prevented epilepsy in most mice. 196 In addition to its known action as an angiotensin II type I receptor inhibitor, losartan exhibits effects on inflammatory pathways and potassium channels 197 that might contribute to its antiepileptogenic effect.
BOX 2 Biomarkers of epileptogenesis after different acquired acute brain insults
A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Categories of biomarkers include:
• Susceptibility/risk biomarkers (eg, epilepsy susceptibility genes or polymorphisms),
• Diagnostic biomarkers (eg, molecular, electrophysiological, or MRI biomarkers), and
• Prognostic biomarkers (eg, molecular and occurrence of pHFOs and rHFOSs).
For further details, see Table S3 and Data S2. MRI, magnetic resonance imaging; pHFO, pathological high-frequency oscillation; rHFOSs, repetitive HFOs and EEG spikes.
Astrocytes control the availability of the brain's endogenous anticonvulsant, adenosine, through expression of adenosine kinase (ADK). 198 As a molecular link between energy homeostasis and metabolic demand, ADK expression undergoes acute downregulation followed by chronic overexpression, triggered by ischemia or TBI, and chemically or electrically induced SE. 54, [199] [200] [201] [202] [203] [204] Overexpression of ADK is linked to astrogliosis and has been reported in human TLE surgical specimens with hippocampal sclerosis and in tumor-associated epilepsy. 202, [205] [206] [207] Increased ADK lowers tissue levels of adenosine, thereby increasing neuronal excitability and precipitating seizures. 200, 203, 208 In addition, increased ADK promotes DNA methylation as an epigenetic contributor to epileptogenesis. 54, 56 Overexpression of ADK has been associated with progression and worsening of epilepsy. 202 Conversely, therapeutic adenosine augmentation 209, 210 suppresses not only seizures but also prevents development and progression of epilepsy in systemic kainate and pilocarpine models. 54, 211 In conclusion, dysfunction of glial K ir channels and gap junctions, and subsequent disruption of K + and adenosine homeostasis are common responses of the brain to TBI, CVA, SE, BBB damage, cortical lesion, and dysplasia, and may contribute to or initiate epileptogenesis. Aquaporin 4, expressed exclusively in astrocytes, is translocated from perivascular astrocytic endfeet to the parenchyma in cortical tissue resected during epilepsy surgery. 212 A role for aquaporin 4 in the disruption of water balance during epileptogenesis is worth following up.
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| INFLAMMATORY PROCESSES AFTER ACQUIRED BRAIN INJURIES
Brain inflammation, or neuroinflammation, 216 is common after TBI, CNS infections, CVA, and SE in humans and animals. Common to all these different acute injuries is the generation of an immune/inflammatory response in CNSspecific cells and cellular components of the BBB. A key common brain response is the rapid activation of microglia, 217 which promptly release an array of frontline inflammatory molecules including damage-associated molecular patterns (eg, high mobility group box-1 [HMGB1], adenosine triphosphate, S100b), cytokines (IL-1b, TNF-a, IL-6), various chemokines, 218 and related effector pathways, including COX-2/PGE2 and complement factors. 36 This shared tissue injury response might be triggered to activate homeostatic programs. However, if the ensuing inflammatory cascade persists, it leads to CNS dysfunction and neuropathology. 36, 217 Nonimmune cells such as astrocytes and neurons, together with the BBB, play an important role in the immune responses to injuries. 36, 176, 219 As various inflammatory molecules contribute to the mechanisms of acute and chronic seizures by altering synaptic transmission and neuronal excitability (Figure 6 ), 220 rodents, [227] [228] [229] IL-6 has a pivotal role in epileptogenesis induced by murine viral encephalitis. 230 Although antiinflammatory drugs dampen epileptogenesis in animal models of SE or viral encephalitis, [228] [229] [230] [231] [232] there is no information on whether inflammation is involved in epileptogenesis after stroke or TBI, 233, 234 except for focal cooling preventing both cortical IL-1 induction and epilepsy after TBI in rats. 61 There is, however, strong evidence that inflammation plays either a pathologic or a beneficial role following TBI or stroke depending on the postinjury phase. 235, 236 Although TNF-a or CX3CR1 knockout mice showed reduced functional deficits compared to wild-type mice acutely post-TBI, their functional recovery over time was impaired and cortical damage was increased. [237] [238] [239] Similarly, TNF-a was involved in both secondary brain damage and regenerative recovery after experimental stroke. [240] [241] [242] The pathologic involvement of inflammation is supported by evidence that excessive brain levels of IL-1b, IL-6, TNF-a (exceeding several times their serum changes), or HMGB1 229, 243, 244 contribute to experimental acute and chronic seizures and SE-induced epileptogenesis. 36, 176, 223 Importantly, HMGB1 antibodies have been shown to prevent epileptogenesis in the mouse intrahippocampal kainate model. 245 Studies of neuroinflammatory changes in postmortem human brain after CVA/ stroke, TBI, infections, and SE are limited, although they are essential to validate the potential pathophysiological role of injury-induced inflammation in epileptogenesis. Encephalitis-induced epilepsy caused by neurotropic viruses 223 is associated with activation of Toll-like receptors, which drives neuronal damage but may also promote tissue repair. 246 The precise relationship between viruses, inflammation, and seizure development requires further studies in animals and humans. We need to better understand the difference between pathologic, and repair and recovery responses, and evaluate more thoroughly potential commonalities across brain injuries, to design drugs with broad therapeutic potential. The term "inflammation" covers many pathways, some of which are beneficial after injury, 235, 236 such that targeted intervention at the right time could succeed when global suppression has failed.
| SIGNALING PATHWAY COMMONALITIES
Four pathways activated after several types of cerebral insults that are associated with epileptogenesis or epilepsy progression are Janus kinase/signal transducer and activator of transcription (JAK/STAT), mammalian target of rapamycin complex (mTORC), BDNF/tyrosine receptor kinase B (trkB)/phospholipase Cc1 (PLCc1), and IL-1R1/Toll-like receptor 4 (TLR4) pathways (Figure 7 ). These signaling pathways mediate cellular physiological mechanisms that are critical for memory formation, long-term depression, and long-term potentiation. The JAK/STAT pathway ( Figure 7A ) is activated after many types of epileptogenic injuries in experimental models, including TBI, SE, and stroke. [247] [248] [249] [250] [251] [252] It regulates expression of genes critical for multiple essential functions including cell proliferation and differentiation, neurogenesis, learning, and memory. JAK/STAT mediates decreases in a1 subunit-containing GABA A receptors in hippocampus that occur after experimental SE and TBI 247, 249 and may contribute to the increased hyperexcitability observed in the hippocampus of injured animals and to subsequent development of epilepsy. Inhibition of STAT3 phosphorylation after SE-induced brain injury reduces the severity of subsequent epilepsy in the rat pilocarpine model, 253 suggesting that JAK-STAT activation after SE may contribute to epileptogenesis. In the CCI model of PTE in mice, the JAK/STAT pathway is differentially activated depending on the severity of brain injury, and correlates with the presence and severity of subsequent cognitive comorbidities. 254 Interestingly, transient inhibition of the JAK/STAT pathway immediately after CCI improved long-term vestibular motor recovery after injury but did not significantly affect memory performance. 254 In rodent models, epileptogenic brain injuries including SE and TBI trigger an immediate and long-lasting increase in the phosphorylation of the S6 ribosomal protein in the hippocampus, which is a downstream marker of an excessively activated mTORC1 pathway ( Figure 7A ). [255] [256] [257] Similarly, structural or dysplastic lesions associated with infantile spasms in rodents or humans also demonstrate overactivation of the mTORC1 pathway in the epileptogenic area. 258 Treatment with mTORC1 inhibitors is antiseizure [259] [260] [261] and in some models of acquired epilepsy, particularly tuberous sclerosis, antiepileptogenic. 256, [262] [263] [264] Excessive activation of the mTORC1 pathway in acquired models of epilepsy is also associated with cognitive and behavioral deficits, which may be reversed following treatment with the mTORC inhibitor rapamycin. 255, 263 Taken together, these findings suggest that JAK-STAT and mTORC1 signaling pathway activation following a variety of brain injuries may contribute to development of acquired epilepsy and comorbid hippocampal-dependent spatial learning and memory deficits. The interaction of BDNF with receptor trkB is involved in fundamental cellular processes including neuronal proliferation, differentiation, and survival as well as neurotransmitter release and synaptic plasticity. Abnormal BDNF-mediated activation of trkB has been reported in various neurological and psychiatric disorders. 265 Altered trkB signaling ( Figure 7B ) underlies epileptogenesis in both the kindling model 35 and after SE, as demonstrated by the ability of trkB inhibitors targeting the PLCc1 signaling pathway that were administered during the latent period to prevent the development of acquired epilepsy in some animals. 98, 266 The IL-1R1/TLR4 pathway (Figure 7A) , activated by IL-1b and HMGB1, contributes not only to acute and chronic seizure recurrence 267 and kindling 268 but also to disease progression post-SE in rodents. 228, 229, 244 11 | PHARMACOLOGY OF ANIMAL
MODELS OF ACQUIRED EPILEPSY
The rat amygdala kindling model of TLE has been extensively studied, 6, 269, 270 although kindled rats do not exhibit spontaneous recurrent seizures (SRS), and therefore lack a defining feature of human TLE. 271 Nonetheless, drugs effective in human TLE are effective against seizures in fully kindled rats. 272 The efficacy of various antiseizure drugs (ASDs) in suppressing seizures in fully kindled rats is remarkably similar to their efficacy in reducing the frequency of SRS in post-SE TLE models (Table 2) . 273 About 20% of kindled rats are resistant to high doses of ASDs such as phenytoin. Similarly, ASD-resistant rats can be selected from post-SE models of TLE. 272 The pharmacology of SRS developing in models of TBI, stroke, or viral encephalitis is largely unknown, with some exceptions. [274] [275] [276] In models of TBI and encephalitis, valproate reduced seizure burden, whereas carbamazepine was ineffective, indicating pharmacologic commonalities. 274, 276 Drug treatment during amygdala kindling acquisition has been used to detect disease-modifying efficacy by F I G U R E 7 Signaling pathway commonalities. Epileptogenic brain injuries, including traumatic brain injury, stroke, and status epilepticus, increase levels of growth factors, cytokines and hormones that activate the (A) JAK/STAT, IL-1R1/TLR4 and mTORC1 signaling and (B) BDNF/trkB/PLCc signaling pathways, resulting in altered expression of genes and proteins involved in cell growth, cell survival, cell proliferation, neurotransmission, learning, and memory, potentially contributing to epileptogenesis and cognitive comorbidities [Color figure can be viewed at wileyonlinelibrary.com] administering drug before each amygdala stimulation. Retardation of kindling development may indicate a true antiepileptogenic action or simply suppression of the effects of the stimulation. For most ASDs the latter is true, whereas for some drugs, including valproate, levetiracetam, and brivaracetam, effects on kindling acquisition (eg, reduced seizure duration) persist long after drug washout, suggesting enduring disease modification. 6, [277] [278] [279] The disease-modifying effects of such drugs have been confirmed in post-SE models of TLE, 6 suggesting that there are shared mechanisms of epileptogenesis in the kindling and SE models. A variety of experimental and clinically approved drugs has been evaluated for antiepileptogenic effects in post-SE models of TLE. 6, 272, 279, 280 Among clinically used ASDs, disease-modifying effects (eg, neuroprotection, prevention Data from post-SE models are from rats in which SE was induced by either systemic pilocarpine or kainate, or electrical stimulation of the basolateral amygdala, or from mice in which SE was induced by intrahippocampal administration of kainate. Data are from L€ oscher. 272, 273 Note that the kindling model correctly predicts efficacy of drugs against focal seizures, whereas the MES test is less predictive in this regard; with some exceptions, doses of antiseizure drugs to suppress kindled seizures are higher than those effective in the MES test. Furthermore, note the correspondence between drug effects on induced amygdala kindled seizures and spontaneously recurrent seizures in post-SE models. NE, not effective; SE, status epilepticus. In hippocampal kindled rats. Responders and nonresponders in post-SE models. 272 of behavioral comorbidities, reduced frequency, duration, or severity of SRS) were only detected after treatment with valproate, levetiracetam, brivaracetam, or topiramate, although none of these drugs prevented epilepsy. 6, 279 Whereas SE models involve significant neuronal loss, neuroprotection alone may be disease-modifying but not antiepileptogenic. 6 Some studies found that anti-inflammatory drugs such as celecoxib or immunosuppressive drugs such as rapamycin exert antiepileptogenic activity in post-SE models, but these effects appear to be very sensitive to the anti-inflammatory drugs used and the timing of drug administration. 6, 258, 279, 281 Interestingly, bumetanide, which inhibits the Na-K-2Cl importer NKCC1 282 and thus increases the hyperpolarizing action of GABA, was not antiepileptogenic in the lithium-pilocarpine SE model in adult rats, 283 although it was reported to have antiepileptogenic actions in a model of complex febrile seizures in rats 284 and in a mouse model of genetic epilepsy. 285 By contrast, in SE models a trkB signaling inhibitor, 98,266 the multitargeted drug isoflurane, which exhibits anti-inflammatory, antioxidative, antiapoptotic, and neuroprotective effects, 286 and HMGB1 antibodies 245 can be antiepileptogenic, providing crucial proof-of-principle that antiepileptogenesis is possible. In addition, inhibition of the IL-1R1/ TLR4 pathway, and the associated reactive oxygen species production, has been shown to mediate disease-modifying effects in different post-SE models. 228, 229, 244 Only a few studies used TBI models to evaluate possible PTE prevention by drug treatment during the latent period. 9 When PTE was induced by rostral parasagittal FPI in rats, 5 weeks of mild focal cooling of the perilesional neocortex almost completely prevented the development of epilepsy, 61 whereas the investigational drug carisbamate exerted no antiepileptogenic efficacy, 275 indicating that the model is capable of detecting antiepileptogenic activity. As noted, losartan prevented epileptogenesis in a PTE model, albeit in high doses. 196 Other studies report antiepileptogenic efficacy of statins in different models, 287 and of minocycline in an encephalomyelitis virus infection model. 288 The preclinical effects of statins were translated to a clinical study. Guo et al. 289 reported that acute statin use reduces the risk of poststroke early onset seizures, and may also prevent the progression of initial poststroke seizures to chronic epilepsy, findings that, if reproducible, would be the first proof-of-concept of antiepileptogenesis in humans. 290 Antiepileptogenic effects of statins are also suggested by 2 other clinical studies. 291, 292 In addition to effects on serum cholesterol levels, statins exhibit immunomodulatory, anti-inflammatory, and antiexcitotoxic properties, 287 which could explain the antiepileptogenic effects that have been observed both experimentally and clinically.
| CONSEQUENCES FOR TRANSLATION AND DEVELOPMENT OF ANTIEPILEPTOGENIC THERAPIES
There are 3 key questions. First, which of the commonalities described in neuropathology, EEG parameters, and molecular and inflammatory pathways are causes rather than consequences of acquired epilepsy? Second, are these commonalities able to clearly distinguish the patients who develop epilepsy from those who have a similar brain insult, but do not develop epilepsy? Third, to what extent do potential causal or susceptibility genes impact the propensity for developing acquired epilepsy? Biomarkers of impending epilepsy are needed to design feasible clinical trials to address these questions. Nonetheless, the richness of commonalities described in this review supports the potential benefit of combinatorial drug treatment, as already demonstrated in preclinical antiepileptogenesis studies. 293 Furthermore, these commonalities also appear to emphasize the promise of systems and network approaches toward identification of master regulators controlling epileptogenesis that may provide drug targets for future antiepileptogenic therapies. [294] [295] [296] The first step in clinical development of antiepileptogenic therapies would be assessment of their safety and tolerability in healthy volunteers, a standard approach for phase I studies. It will be advantageous to demonstrate target engagement in the brain before moving into later stages, to reduce the risk of development failure. 297, 298 A newly developed synaptic density marker appears promising to measure neurodegeneration and neuronal network changes during epileptogenesis. 299 Other indirect target engagement measures could include quantitative EEG or magnetoencephalographic techniques 300 or assessment of specific molecular biomarkers in plasma that are clearly linked with drug activity in the brain. Development of such clinical biomarkers (Box 2) should be performed in parallel with the preclinical drug development of antiepileptogenic drug candidates. Antiepileptogenesis studies should be performed in homogenous patient cohorts sharing similar clinical features such as, for example, severity of injury, accumulation of intracranial blood, and incidence of early seizures, because these appear to be common and most likely predictors of focal epilepsy development (Table 3) . Other important stratification factors should include the commonality in early EEG parameters (eg, HFOs) and similarities in the involvement of the epileptogenic limbic structures (eg, MRI). Furthermore, whenever possible, stratification based on molecular biomarkers should be applied (Box 2). Subjects sharing involvement of similar mechanisms such as dysregulation of the JAK-STAT, mTOR, or BDNF/trkB Depending on the clinical development strategy, proofof-concept studies should accumulate evidence that the onset of epilepsy is delayed after brain injury (ideally prevention of epilepsy) or that core clinical features of an ongoing epilepsy are substantially altered (disease modification). The standard ASD add-on trial design and seizure outcome may be used, the difference being that the followup period may need to be much longer in prevention trials to demonstrate a therapeutic effect after withdrawal of the antiepileptogenic agent. 3, 280, 303 Clinical development of drug combinations is associated with a number of significant challenges; therefore, the U.S. Food and Drug Administration (FDA) issued practical guidelines to facilitate this process. 304, 305 It is certainly more straightforward to develop a combination treatment that consists of previously approved medications than 2 or more investigational drugs used in combination. However, regardless of the approval status of the drug constituents, the New Drug Application submitted to the FDA should contain appropriate data to establish the overall safety and effectiveness for the new dosing regimen or indication as proposed in the combination product. Even in the case of previously approved drugs, such data may not be easily obtainable or compatible with the proposed drug combination, new indication, or treatment regimen. The biggest challenge in development of combinatorial drug treatments is the need to demonstrate that each constituent contributes to the efficacy. This typically involves the necessity to include single drug arms in the trial, which considerably increases the complexity of the design, overall study duration, and costs. It is even more challenging if the optimal doses of each drug are not yet defined, which may require additional dose-finding studies for each drug alone or in combination. Finally, even before embarking on clinical trials, additional preclinical data may be needed (eg, safety/toxicology, pharmacokinetics [drug-drug interactions], target/biomarker interactions).
Lastly, there may be legal, intellectual property, and freedom-to-operate limitations, particularly for approved drugs used in combination. This may further complicate the development and commercialization of the new combinatorial product.
| CONCLUSIONS AND FUTURE
DIRECTIONS
The data reviewed indicate that there are a number of commonalities among the 3 main acute CNS injuries that lead to epilepsy in humans-TBI, CVA, and infection. At the clinical level, the presence of intracranial blood, breakdown of the BBB, severe injury, early clinical seizures and EEG seizures, and periodic discharges on early EEG increase the risk for epilepsy in all three. Common anatomical modifications include astrocytosis, white matter abnormalities impacting seizure network and propagation, and neuronal heterotopia. Common elements in animal models include involvement of anatomically constrained networks that relay and distribute seizures remotely from the initial locus of injury, which can explain the common phenomenon of secondary epileptogenic involvement of the temporal lobe, activation of astrocytes with impairment of extracellular K + buffering and of adenosine homeostasis, selective death of inhibitory interneurons and disinhibition/overinhibition of primary excitatory cells, and activation of the JAK/STAT and mTORC1 pathways. On the other hand, transcriptomics have as yet shown few shared gene expression changes across (or within) models, and the role of neuroinflammation and BDNF/trkB signaling in epileptogenesis has been demonstrated in SE and kindling models but has not yet been evaluated in animal PTE and PSE. Whether the causes of epilepsy share common mechanisms and features with the causes of the most common comorbidities (anxiety, depression) is an important question to pursue. Review of the data suggests several conclusions:
1. The 3 common causes of epilepsy after acute injury, TBI, CVA, and infection, share enough risk factors, electrophysiology, and pathology features to possibly consider them, in epileptogenesis, as one broad category (with individual variations). This has major implication for preventive therapeutic development. To validate or disprove this hypothesis, we should target comparison of epileptogenic processes as well as potential biomarker discovery and therapeutic intervention in both clinical and animal studies comparatively across the 3 types of injury, particularly for TBI and CVA, where clinical intervention is logistically most feasible. If the hypothesis proves correct, this would allow a broader approach to development of biomarkers of epileptogenesis and of preventive treatments.
2.
It is still unclear whether data obtained from the logistically easier models of SE and kindling are applicable to the human conditions of TBI, CVA, and infection, because relevant data do not exist. This calls for a concerted effort to systematically evaluate the SE and kindling model findings in the PTE, PSE, and infection models. Answering this question will determine whether biomarker and therapeutic intervention studies, which can more easily be done in SE and kindling models, have relevance for human preventive treatment discovery. If they do, this would facilitate translation from animal to clinical studies. 3. Finally, this review identifies a plethora of potential biomarkers, as well as preclinical evidence for several preventive therapeutic strategies that can be followed in human studies. Clinical preventive studies may be significantly strengthened if the preclinical studies are systematically evaluated across the different animal models. Perhaps epileptogenic features, biomarkers, and positive treatments common to all the animal models may have the greatest chance of clinical success and lead, at long last, to a breakthrough in preventive and/or disease-modifying treatment for epilepsy. 
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